PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no [redacted]s are required to respond to a collection of information unle[redacted]ntains a valid OMB control number

DT01 Rec'd PCT/PT 23 DEC 2004

Substitute for Form 1449/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/519388
	Filing Date	
	First Named Inventor	Helmut SCHMIDHAMMER
	Art Unit	
	Examiner Name	
Sheet 1 of 2	Attorney Docket Number	1739-10PUS

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. [1]	Document Number Number-Kind-Code [2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CA		US-4,272,540	6-9-81	Razdan et al.	
CA		US-4,390,699	6-28-83	Brossi et al.	
CA		US-4,912,114	3-27-90	L. Revesz	
CA		US-4,176,186	11-27-79	Goldberg et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. [1]	Foreign Patent Document Country Code [3] Number [4] Kind-Code [5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
CA		UK 1,300,419	12/20/72	W. R. Buckett et al.		
CA		EP 0 250 796	1/7/88	E. I. Du Pont De Nemours and Co.		
CA		DE 3412727 A1	10/17/85	A. Gleich		
CA		EP 0 030 685 A2	6/24/81	R. K. Razdan et al.		
CA		WO2004/005294 A2	1/15/04	H. Schmidhammer et al.		

Examiner Signature	ALLAKH	Date Considered	4/25/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no [redacted]s are required to respond to a collection of information unle[redacted]ntains a valid OMB control number

Substitute for Form 1449/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10751938
	Filing Date	
	First Named Inventor	Helmut SCHMIDHAMMER
	Art Unit	
	Examiner Name	
Sheet 2 of 2	Attorney Docket Number	1739-10PUS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CA		Chen-Yu Cheng, et al., "*N*-Cubylmethyl Substituted Morphinoids as Novel Narcotic Antagonists", Bioorganic & Medicinal Chemistry, Vol. 4, No. 1, pp 73-80, 1996.	
CA		A. Coop, et al., "Delta Opioid Binding Selectivity of 3-Ether Analogs of Naltrindole", Bioorganic & Medicinal Chemistry Letters, 9 (1999) 3435-3438.	
CA		J. Schütz, et al., "Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 17. Highly δ Opioid Receptor Selective 14-Alkoxy-Substituted Indolo- and Benzofuromorphinans", J. Med. Chem. 2002, 45, 5378-5383.	
CA		H. Schmidhammer, et al., "Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 1. Highly Potent Opioid Agonists in the Series of (-) - 14 Methoxy-*N*-methylmorphinan-6-ones", J. Med. Chem., 1964, 27, 1575-1579.	
CA		P. Klein, et al., "O^3-(2-Carbomethoxyallyl) Ethers of Opioid Ligands Derived from Oxymorphone, Naltrexone, Etorphine, Diprenorphine, Norbinaltorphimine, and Naltrindole. Unexpected O^3-Dealkylation in the Opioid Radioligand Displacement Assay", J. Med. Chem., 1992, 35, 4589-4594.	
CA		P.S. Portoghese, et al., "Synthesis of Naltrexone-Dervied δ-Opioid Antagonists. Role of Conformation of the δ Address Moiety", J. Med. Chem., 1994, 37, 579-585.	
CA		C. W. Funke, et al., "A ^{1}H and ^{13}C Nuclear Magnetic Resonance Study of Three Quaternary Salts of Naloxone and Oxymorphone", J. Chem. Soc. Perkin Trans. II, 1986, Pages 735-738.	

Examiner Signature	ALLACH	Date Considered	4/25/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.